Using Clinical Information To Project Federal Health Care Spending

被引:13
作者
Huang, Elbert S. [1 ]
Basu, Anirban [1 ]
O'Grady, Michael J. [2 ]
Capretta, James C. [3 ]
机构
[1] Univ Chicago, Gen Internal Med Sect, Sch Med, Chicago, IL 60637 USA
[2] OGrady Hlth Policy LLC, Chevy Chase, MD USA
[3] Civ Enterprises LLC, Washington, DC USA
关键词
IMPROVING DIABETES CARE; COST-EFFECTIVENESS; TYPE-2; MODEL; OUTCOMES; NIDDM;
D O I
10.1377/hlthaff.28.5.w978
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Complications from chronic illnesses often do not emerge for many years. Current federal cost projection methods are constrained by ten-year cost estimates, which capture increases in near-term intervention costs but not changes in long-term costs. Current methods also cannot easily capture the cost implications of changes in disease progression. Type 2 diabetes is a prime example of a chronic illness with long-term health and cost consequences. We present results from an epidemiologically based model that projects federal costs for diabetes under alternative policies, and we discuss the potential changes in the federal budget process needed to capture the full impact of these interventions. [Health Aff (Millwood). 2009; 28(5): w978-90 (published online 1 September 2009; 10.1377/hlthaff.28.5.w978)]
引用
收藏
页码:W978 / W990
页数:13
相关论文
共 24 条
[1]  
Antos J R., 2002, Issues in designing a prescription drug benefit for Medicare
[2]   Meta-analysis: Chronic disease self-management programs for older adults [J].
Chodosh, J ;
Morton, SC ;
Mojica, W ;
Maglione, M ;
Suttorp, MJ ;
Hilton, L ;
Rhodes, S ;
Shekelle, P .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (06) :427-438
[3]   A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) [J].
Clarke, PM ;
Gray, AM ;
Briggs, A ;
Farmer, AJ ;
Fenn, P ;
Stevens, RJ ;
Matthews, DR ;
Stratton, IM ;
Holman, RR .
DIABETOLOGIA, 2004, 47 (10) :1747-1759
[4]  
Congressional Budget Office, 2007, LONG TERM BUDG OUTL
[5]  
CRIPPEN D, 2002, TESTIMONY DIS MANAGE
[6]   The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients [J].
Crivera, C. ;
Suh, D. C. ;
Huang, E. S. ;
Cagliero, E. ;
Grant, R. W. ;
Vo, L. ;
Shin, H. C. ;
Meigs, J. B. .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (11) :2301-2311
[7]  
DeVol R., 2007, UNHEALTHY AM EC BURD
[8]   Model of complications of NIDDM .1. Model construction and assumptions [J].
Eastman, RC ;
Javitt, JC ;
Herman, WH ;
Dasbach, EJ ;
Zbrozek, AS ;
Dong, F ;
Manninen, D ;
Garfield, SA ;
CopleyMerriman, C ;
Maier, W ;
Eastman, JF ;
Kotsanos, J ;
Cowie, CC ;
Harris, M .
DIABETES CARE, 1997, 20 (05) :725-734
[9]   Validation of the archimedes diabetes model [J].
Eddy, DM ;
Schlessinger, L .
DIABETES CARE, 2003, 26 (11) :3102-3110
[10]   ONSET OF NIDDM OCCURS AT LEAST 4-7 YR BEFORE CLINICAL-DIAGNOSIS [J].
HARRIS, MI ;
KLEIN, R ;
WELBORN, TA ;
KNUIMAN, MW .
DIABETES CARE, 1992, 15 (07) :815-819